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456pregnancy with a strategy of thrombus removal is
safe and avoids post-thrombotic morbidity
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Shiraz Sunderji, MD,b Robert DiSalle, MD,c Sahira N. Kazanjian, MD,c and Zakaria Assi, MD,c Toledo, Ohio
Background: Extensive deep venous thrombosis (DVT) during pregnancy is usually treated with anticoagulation alone,
risking signiﬁcant post-thrombotic syndrome (PTS) in young patients. Catheter-directed thrombolysis (CDT) and
operative venous thrombectomy have been safely and effectively used in nonpregnant patients, demonstrating signiﬁcant
reduction in post-thrombotic morbidity. This report reviews short- and long-term outcomes of 13 patients with extensive
DVT of pregnancy treated with a strategy of thrombus removal.
Methods: From 1999 to 2013, 13 patients with iliofemoral DVT during pregnancy were offered CDT, pharmacomechanical
thrombolysis (PMT), and/or venous thrombectomy. Gestational age ranged from 8 to 34 weeks. Fetal monitoring was per-
formed throughout hospitalization. Radiation exposure was minimized with pelvic lead shields, focal ﬂuoroscopy, and limited
angiographic runs. Follow-up includedobjective vein evaluationusingvenousduplex andPTSassessmentusing theVillalta scale.
Results: CDT and/or PMT were used in 11 patients. Two patients underwent venous thrombectomy alone, and one
patient had operative thrombectomy as an adjunct to CDT and PMT. Each patient had complete or near-complete
thrombus resolution and rapid improvement in clinical symptoms. Eight of 11 having CDT or PMT underwent veno-
plasty and stenting of the involved iliac veins. Twelve of the 13 delivered healthy infants at term. One patient opted for
termination of her pregnancy. Mean patient and gestational ages were 26 years and 26 weeks, respectively. Mean follow-
up was 1.3 years, with only one recurrence. Duplex ultrasonography demonstrated patent veins in all but one patient and
normal valve function in 10 patients. Eleven patients had Villalta scores <5 (considered normal), with a mean score of 0.7.
Conclusions: Extensive DVT of pregnancy can be effectively and safely treated with a strategy of thrombus removal,
resulting in a patent venous system, normal valve function in many, prevention of PTS, and reduction in recurrence.
(J Vasc Surg 2014;59:456-64.)Deep venous thrombosis (DVT) is a signiﬁcant cause of
morbidity during pregnancy and the postpartum period.
Venous thromboembolic disease complicates approximately
1 to 2 per 1000 pregnancies, with maternal age, comorbid-
ities, andmode of delivery inﬂuencing the risk.1-3 Treatment
options range from management with heparin anticoagula-
tion alone until delivery to catheter-based thrombolytic
techniques or operative thrombectomy. However, extensive
DVT during pregnancy is usually treated with anticoagula-
tion alone, risking signiﬁcant post-thrombotic morbidity.4,5
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had thrombus involving the iliofemoral veins.6 Iliofemoral
DVT is associated with a high risk of post-thrombotic
syndrome (PTS),4,5,7 a debilitating condition that reduces
quality of life and often worsens over time. The prospect
of post-thrombotic morbidity in this cohort of young and
otherwise healthy women should motivate physicians to
consider a strategy of thrombus removal.
Adopting a strategy of thrombus removal and restoring
patency to the iliofemoral segment reduces short- and
long-term morbidity in iliofemoral DVT patients.8,9 The
combination of early clot removal with catheter-based
techniques or contemporary venous thrombectomy,
correction of underlying residual stenosis with balloon
venoplasty and/or stenting, and systemic therapeutic anti-
coagulation is becoming the preferred treatment option for
iliofemoral DVT in the nonpregnant patients in centers
with appropriate expertise.10-12
DVT of pregnancy is uniformly treated with only
anticoagulation, regardless of its extent. Even when preg-
nant patients present with phlegmasia cerulea dolens,
the most common clinical presentation of iliofemoral
DVT, vascular surgeons fail to offer venous thrombectomy,
and interventionalists avoid catheter-based techniques of
thrombus removal for fear of treatment-related pregnancy
complications.
We have observed that patients with extensive DVT of
pregnancy who have persistent pain and edema with
Fig 1. A 24-year-old patient, 32 weeks pregnant, presented with a 2-week history of left iliofemoral deep venous
thrombosis (DVT) causing severe pain and swelling of her left leg, unresponsive to low-molecular-weight heparin
(LMWH) and leg elevation. Venography revealed iliofemoral DVT from the proximal femoral vein and common
femoral vein to the vena cava. A, Ascending venogram shows the thrombosed proximal femoral and common femoral
veins and (B and C) a patent vena cava with compression by a gravid uterus.
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and effectively with a strategy of thrombus removal. The
purpose of this report is to objectively describe the treat-
ment and outcome of 13 consecutive patients treated
with either catheter-based techniques or operative throm-
bectomy for iliofemoral DVT of pregnancy.
METHODS
Between 1999 and 2013, 13 patients were referred for
management of extensive DVT during pregnancy. All
patientswere initiallymanagedwith systemic anticoagulation
and leg elevation and had persistent pain and edema after 2
to 14 days of treatment. After failing initial anticoagulation
and elevation, patients were offered a strategy of thrombus
removal. Patient data were collected and retrospectively
reviewed to evaluate treatment and pregnancy outcomes.
The study was approved by the institutional review board.
All patients presented with extensive lower extremity
DVT involving the iliofemoral venous segments and had
swollen limbs from the inguinal ligament distally that
were painful and had bluish discoloration, classically known
as phlegmasia cerulea dolens. All were offered a strategy
of thrombus removal, which included catheter-directed
thrombolysis (CDT), pharmacomechanical thrombolysis
(PMT), or operative venous thrombectomy. Percutaneous
interventions were all performed using conscious sedation
with fentanyl and midazolam, with midazolam used
cautiously during the third trimester. All patients were
monitored with electrocardiography, pulse oximetry, and
vital signs by experienced interventional nurses. Obstetrical
nurses oversaw the fetal monitors measuring fetal heart rate
and uterine contractions during the procedures. Radiation
exposure was minimized. The patient’s abdomen and pelviswere shielded with a lead apron when possible, and low-
frame (four to six frames per second) pulse ﬂuoroscopy
with ﬂuoro-save were used during all interventions. Digital
subtraction angiographic runs were kept to a minimum and
conﬁned to the inferior vena cava (IVC) and iliac veins.
The ﬁeld of ﬂuoroscopy was tightly collimated. Fluoro-
scopic image hold was used for documenting and ﬁlming.
Foley catheters were used in all patients.
Most patients were able to tolerate a prone or semi-
decubitus position. The preferred access site for percuta-
neous interventions was the ipsilateral popliteal vein, but
two patients required additional posterior tibial vein access
at the ankle level due to DVT extending below the popli-
teal vein into the calf veins. Internal jugular or contralateral
common femoral vein access was used when IVC ﬁlter
placement was required, which occurred when free-
ﬂoating clot protruding into the vena cava was noted
during venography. Optional Gunther-Tulip ﬁlters (Cook
Medical, Bloomington, Ind) were placed in the suprarenal
IVC, with retrieval performed after delivery.
All access sites were prepped with 4% chlorhexidine and
draped in the usual fashion. Veins were accessed using
ultrasound guidance and 4-F micropuncture needles
(Cook Medical). Following venography, a 6- to 8-F access
sheath was placed in the popliteal vein, and the clot was
traversed with a hydrophilic guidewire. An intravascular
ultrasound catheter (Volcano, San Diego, Calif) was occa-
sionally used to evaluate the extent of central venous
thrombosis or to guide stent placement.
PMT was performed using an 8-F Trellis catheter
(Covidien, Mansﬁeld, Mass) to perform isolated segmental
PMT or a 6-F AngioJet catheter (Medrad, Warrendale, Pa)
used for rheolytic thrombectomy, occasionally supplemented
Fig 2. The patient underwent isolated, segmental, pharmaco-
mechanical thrombolysis (PMT) with the Trellis catheter (Covi-
dien, Mansﬁeld, Mass), which removed a large bulk of the
thrombus and restored patency to the iliac and common femoral
veins.
JOURNAL OF VASCULAR SURGERY
458 Herrera et al February 2014with traditional balloon maceration. Eight- to 20-mg recom-
binant tissue plasminogen activator (rt-PA) was used in the
initial session. In 10 of 11 patients treated with CDT and/
or PMT, additional rt-PA infusion was required overnight.
CDT was performed using a 4- to 5-F Unifuse catheter
(Angiodynamics, Latham, NY) or a 6-F EKOS ultrasound-
accelerated thrombolysis catheter (EKOS Corp, Bothwell,
Wash), with rt-PA infused at 1 mg/hr diluted in 35-mL
(EKOS) or 50- to 100-mL saline (Unifuse). When necessary,
and upon completion of successful lysis, self-expanding
stents were deployed to treat an underlying chronic stenosis
of the common iliac (14-16 mm) and external iliac veins(12-14 mm); stents used included Zilver (Cook Medical),
Luminex (Bard, Tempe, Ariz), and Wallstent (Boston Scien-
tiﬁc, Natick, Mass). In one particularly challenging case, the
patient required overlapping stent grafts (10  60, 10 
40) in the femoral and common femoral vein segments.
Patients received 4000 to 7000 units of heparin during
the procedure and were therapeutically anticoagulated with
heparin postprocedure. They were discharged on enoxaparin
1 mg/kg every 12 hours for the duration of pregnancy, and
converted to vitamin K antagonists postdelivery to a target
international normalized ratio of 2.0 to 3.0. Anticoagulation
was continued for a minimum of 12 months. When antico-
agulation was discontinued, patients were placed on aspirin
81 mg daily. Following intervention, leg compression with
30- to 40-mm Hg ankle gradient below-knee stockings
was applied, and patients were ambulated. Follow-up con-
sisted of objective evaluation of the veins using segmental
venous duplex and assessment of the presence and severity
of their PTS using the Villalta scale.
RESULTS
All patients presented with acute occlusive iliofemoral
DVT causing lower extremity symptoms of pain, swelling,
bluish discoloration, and heaviness, most with the typical
clinical presentation of phlegmasia cerulea dolens. All
patients were initially treated with therapeutic anticoagula-
tion and leg elevation for 2 to 14 days and had persistent
pain and edema. Three patients had such severe pain and
swelling that they could not ambulate. One patient, treated
for 9 days with heparin prior to referral, had a painful ﬂexion
contracture of her knee. Mean age was 26 years (range,
19-35 years) and mean gestational age was 26 weeks (range,
6-34 weeks). Two patients were in the ﬁrst trimester, two
in the second, and nine in the third trimester. It was the ﬁrst
pregnancy for nine patients. All patients had iliofemoral
involvement, two of whom had thrombus extending into
their popliteal and tibial veins, and two had thrombus
involving their vena cava. Figs 1-8 summarize the most
challenging patient in our series, who was also the most
instructive regarding pathophysiology, residual thrombus,
and inﬂammation of the vein wall.
CDT or PMT techniques were used in 11 patients.
Two patients with iliofemoral DVT declined thrombolytic
therapy but consented to operative venous thrombectomy.
A third patient had operative thrombectomy as an adjunct
to PMT to remove persistent thrombus. Two patients had
successful lytic therapy antepartum; however, venoplasty
and stenting were delayed until the postpartum period.
Because of uterine compression on the iliac veins and
cava, the presence or absence of intrinsic iliac vein stenosis
was not certain in these patients. They were anticoagulated
until delivery and had repeat iliocavagrams postpartum.
The repeat venograms demonstrated residual iliac vein
stenoses, which were then dilated and stented.
IVC ﬁlters were placed in two patients due to nonoc-
clusive thrombus in the vena cava at presentation, and post-
partum ﬁlter retrieval was successful in one. All patients had
complete or near-complete thrombus resolution with rapid
Fig 3. Residual thrombus in the femoral vein was treated overnight with the ultrasound-accelerated EkoSonic throm-
bolytic system (EKOS Corp, Bothell, Wash) infusing 1-mg recombinant tissue plasminogen activator (rt-PA) per hour.
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delivered healthy infants at term. One patient was noncom-
pliant with her low-molecular-weight heparin (LMWH)
after discharge and was readmitted with recurrent femoro-
popliteal DVT 1 week later. This patient elected to termi-
nate her pregnancy.
The mean skin dose of radiation, based on a readout of
the C-arm, was 447 mGy (range, 86-815 mGy). Actual
patient dosimetry can be different based on location of
the patient and table movement. The readout of an
external dosimeter placed on the patient’s pelvis overlying
the fetus was available in one patient. The dosimeter
recorded 55.3 mGy compared with 86 mGy displayed by
the C-arm readout. This suggests a 55% overestimation
of the skin dose by the C-arm.
There were three minor complications, which were
puncture site hematomas. One patient required a single
blood transfusion. Two major complications occurred in
one patient: gross hematuria, which was attributed to
trauma of a Foley catheter, required three transfusions
postlysis, while the patient was on heparin. The same
patient developed a left popliteal artery pseudoaneurysm,
which was successfully obliterated with compression ultra-
sound. One patient was lost to follow-up after treatment
and successful delivery.
Mean follow-up was 1.3 years (range, 1-74 months).
Venous duplex ultrasonography demonstrated patent veinsin 12 of 13 patients and normal valve function in 10 (77%).
Eleven (85%) patients had Villalta scores <5, indicating
a normal evaluation.13 Three patients had uneventful
subsequent pregnancies, all managed with subcutaneous
LMWH during pregnancy and the peripartum period.
There were no pregnancy or postpartum complications.
One patient who discontinued her anticoagulation prema-
turely developed recurrent DVT.
DISCUSSION
Venous thromboembolic disease remains a signiﬁcant
cause of morbidity during pregnancy and the postpartum
period. The relative risk of developing venous thromboem-
bolism is increased ﬁvefold during pregnancy and the
postpartum period, with the incidence ranging from 1 to
2 per 1000 pregnancies.1-3 Venous thromboembolic events
occur more frequently during the last 20 weeks of preg-
nancy, especially among the youngest (15-19 years) and
the oldest (>35 years) women.2 The incidence of DVT
during pregnancy is three times higher than that of pulmo-
nary embolism.2
Most physicians and guideline writing committees
recommend treating DVT of pregnancy with anticoagula-
tion alone.14,15 The use of CDT techniques is suggested
only in cases of life-threatening pulmonary embolism.15
Although several reports have demonstrated that DVT of
pregnancy treated with anticoagulation alone resulted in
Fig 4. Repeat venography demonstrated a patent iliac system but
(A) segmental continued segmental obstruction of the proximal
femoral vein. Venoplasty resulted in recoil. A recommendation was
made for operative venous thrombectomy.
Fig 5. Operative exposure revealed a markedly inﬂamed and
thickened vein wall measuring 4 mm in thickness (A). B, Following
removal of the adherent thrombus, a bovine pericardial patch was
used to close the venotomy and the patient was maintained on
heparin via a catheter in her popliteal vein and returned to the
intensive care unit.
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impaired quality of life,16-18 a 16-year follow-up of DVT
of pregnancy in 25 patients treated medically reported
that 52% had no clinical signs of venous disease.19
However, the precise extent and burden of clot was not
well described.
CDT and PMT techniques have demonstrated good
results in the nonpregnant population.9,11,20-23 A recently
reported randomized trial showed that patients treated
with CDT had less PTS than those treated with anticoagu-
lation alone, and that patient beneﬁt was related to the
patency of the iliofemoral venous system.23 Unfortunately,only 37% in the anticoagulation arm and 45% in the throm-
bolysis arm were treated for iliofemoral DVT. This may
explain why the number needed to treat to avoid PTS
was seven. Clinically relevant bleeding complications
occurred in 8%. Reports of thrombolysis for treating
DVT in pregnancy are relatively few and primarily consist
of case reports.24-26 A literature search performed by Leon-
hardt et al26 included 28 reports of thrombolysis with
rt-PA used to treat venous thromboembolism during preg-
nancy; however, only three of the 28 reports described
treatment of DVT, all of which were successful. We believe
our series of 13 consecutive patients treated with strategies
of thrombus removal for iliofemoral DVT of pregnancy (11
with catheter-directed rt-PA) is the largest report to date.
Our patients were thought to be at particularly high risk
of PTS because of the extensive nature of their clot and
their persistent symptoms and signs despite therapeutic
anticoagulation and leg elevation.
Pregnancy is considered a relative contraindication to
thrombolytic therapy. However, the amount of plasmin-
ogen activator actually delivered with current techniques
is a fraction of that delivered with systemic therapy. Some
have expressed concern about the transfer of thrombolytic
agents across the placenta; however, the large molecular
weight of most thrombolytic agents indicates they are
Fig 6. Repeat venography on postoperative day 2 showed reoc-
clusion of her femoral and common femoral veins.
Fig 7. The femoral and common femoral segments underwent
rheolytic thrombectomy and were dilated to 10 mm with a residual
high-grade stenosis refractory to balloon dilation. Two overlapping
stent grafts (10  60; 10  40) were placed that did not cross the
inguinal ligament. Stent grafts were chosen because of the marked
inﬂammatory changes in the femoral veins, anticipating that the
inﬂammation would more rapidly subside if blood was not in
contact with the vein wall.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 2 Herrera et al 461unlikely to cross the placenta during treatment.27 All
patients in this series treated with catheter-based tech-
niques received rt-PA, which has the largest molecular
weight of the available thrombolytic agents.27 Further-
more, most patients were treated with CDT or PMT tech-
niques, thereby localizing the delivery of rt-PA to the
affected venous segments and minimizing its systemic lytic
effect.
Systemic thrombolytic therapy has been used during
pregnancy to treat stroke, pulmonary embolism, thrombosis
of prosthetic cardiac valves, and myocardial infarction.28 No
maternal or fetal toxicity is evident at a 1-mg/kg dose,
which is larger than the doses used in our patients.
Operative venous thrombectomy has been shown to
restore luminal patency, eliminate the embolic source,
and reduce post-thrombotic morbidity in patients with ilio-
femoral DVT.29-31 Pillny et al32 reported on 97 women
with DVT of pregnancy treated with operative venous
thrombectomy. Although there were no maternal deaths,
there were ﬁve fetal deaths at 2 to 10 weeks due to abrup-
tion of the placenta. This is likely a reﬂection of the under-
lying pathophysiology leading to the patients’ thrombotic
event rather than a complication of treatment. At a meanfollow-up of 6 years, 56% of women had no post-throm-
botic symptoms, 36% had mild symptoms, and 8% had
severe PTS. Three of our patients were treated successfully
with operative venous thrombectomy.
Diagnostic evaluation should be pursued with compres-
sion ultrasonography, magnetic resonance imaging, and
venography, with limited patient exposure to computed
tomography scans due to the associated radiation dose.
D-dimer levels naturally increase during pregnancy and
may also be elevated in certain pregnancy complications
such as abruption, preeclampsia, and sepsis. As in most
nonpregnant patients, the value of a D-dimer test is when
it is normal, not when it is elevated.33 If DVT is suspected,
LMWH or unfractionated heparin should be started
immediately, especially if conﬁrmatory diagnostic tests are
delayed. A negative duplex scan of the infrainguinal veins
does not rule out the presence of more proximal clot if iliac
veins are not visualized, and further testing should be consid-
ered. Anticoagulation, leg elevation, and compression
should be used in all patients with DVT.
Once the diagnosis is conﬁrmed, imaging of the vena
cava is essential if a strategy of thrombus removal is to be
implemented. If nonocclusive thrombus is present in the
vena cava, a suprarenal optional IVC ﬁlter will be inserted,
with plans for retrieval after delivery. During treatment, all
measures to prevent radiation exposure were implemen-
ted. These included: (1) reduced rate pulsed ﬂuoroscopy;
Fig 8. The following morning, the patient underwent her fourth and ﬁnal venogram, conﬁrming patency. The patient
subsequently did well without post-thrombotic signs or symptoms. She had a second child 2 years later and was treated
with low-molecular-weight heparin (LMWH) throughout pregnancy. She is now a long-distance runner competing in
marathons. She continues to demonstrate patent veins with normal valve function.
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(4) ﬁlming performed in an anterior-posteriormanner rather
than an obliquely or angled position. Most of our patients
were exposed to two iliocavagrams and one to two unilateral
venograms, which roughly amounts to 0.942 rads, well
below the dose levels (5 rads) demonstrated by epidemio-
logic studies that show risk for fetal injury.34 Two out of
the three phlebograms were for therapeutic purposes. Two
minutes of ﬂuoroscopy to the abdomen exposes the area to
0.5 rads of irradiation, which is well within the 5-rad safety
limit.
Following successful lysis, correction of an underlying
venous stenosis, commonly in the iliac vein, is recommen-
ded. In all but one patient, stents were limited to the iliac
veins. In the case reviewed in detail in Figs 1-8, a covered
stent was used because of the marked inﬂammatory
response of the vein wall associated with rethrombosis
while the patient was therapeutically anticoagulated with
catheter-directed heparin infusion. We thought that
excluding contact of blood with the inﬂamed vein wall
would be the least thrombogenic option and would lead
to the most rapid resolution of the inﬂammation. This
was the only stent graft used to treat residual disease
following CDT for acute DVT in our entire experience.
We avoid the use of stent grafts in the venous system;
however, we thought it was the best option in this patient
for the reasons stated.
The intent of a strategy of thrombus removal in
patients with extensive DVT is to prevent PTS and reduce
the risk of recurrence. It appears that successfully applied to
these young patients, that goal was achieved. Iliofemoral
DVT is the single most powerful predictor of severe
PTS.4,7 Intuitively, this is evident, since the common
femoral vein and iliac veins are the single channel forvenous return from the leg to the vena cava and, if
obstructed, result in the highest venous pressures.35 It
was gratifying that 85% of our patients had no evidence
of PTS on long-term follow-up. Comerota et al36 recently
reported that in patients with iliofemoral DVT treated with
CDT, PTS was linearly correlated with the amount of
residual thrombus at the end of CDT.
Patients with iliofemoral DVT have the largest burden
of thrombus. A systematic review by Hull et al37 reported
that when patients are treated with anticoagulation alone,
recurrence occurs signiﬁcantly more frequently in patients
with large thrombus burdens. Douketis et al38 reported
that recurrence in patients with iliofemoral DVT occurred
2.4 times more frequently than in patients with infraingui-
nal DVT. One would have expected a 35% to 40% recur-
rence rate in our patients if they were treated with
anticoagulation alone. Since only one (8%) experienced
recurrence, 92% had patent veins, and 77% had normal
valve function, our results suggest that successful thrombus
removal is important in reducing subsequent venous
thromboembolic events. Aziz et al39 recently reported
a signiﬁcant correlation of recurrent DVT with the
thrombus burden remaining at the end of CDT. These
observations by Aziz are supported by the patients in the
present study. The implications of recurrence are substan-
tial, since patients with recurrent DVT are generally treated
with lifelong anticoagulation40 with its attendant inconve-
nience and risks.
CONCLUSIONS
Iliofemoral DVT in pregnancy can be treated safely
with a strategy of thrombus removal to reverse short- and
long-term morbidity. Operative and catheter-based tech-
niques can be tailored to the speciﬁc needs of the patient.
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thrombolysis and ultrasound-accelerated thrombolysis
lessen exposure to lytic agents and shorten treatment dura-
tion. Successful thrombus clearing avoids post-thrombotic
morbidity and appears to reduce recurrence in these other-
wise healthy young women.
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